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Summary
Background: Padma 28 is an herbal formula from Tibetan 
Medicine, which since 35 years has been registered in Swit-
zerland as a drug for the symptoms of circulatory disorders. 
Over this time, a large body of scientific literature has accu-
mulated. The aim of this article was to give an overview of 
the clinical studies. Methods: A systematic literature search 
was done in PubMed, EMBASE, and the Cochrane Central 
Register of Controlled Trials (CCRCT). The clinical trials found 
were assessed regarding fields of application, efficacy, and 
safety, as well as methodological quality and level of evi-
dence. Results: 29 trials (1 meta-analysis, 21 controlled trials, 
7 open trials) and 3 retrospective case studies were found. 
They deal with different indications and include a total of 
1,704 verum (of these, 697 children), 333 placebo, and 394 un-
treated or healthy patients. Dropouts and withdrawals were 
2.5 and 3.5 times higher in the placebo than in the verum 
group, respectively. The highest level of evidence for the use 
of Padma 28 was found in the indication of intermittent clau-
dication (11 trials). Indications of efficacy were also found in 
other vascular (6 trials) and different inflammatory diseases 
(12 trials). Conclusions: The results suggest a favorable safety 
profile for Padma 28, also in the children examined (41% of 
the study population). Furthermore, the results show a broad 
field of applications. According to clinical evidence, Padma 28 
has shown to be a safe and effective symptomatic treatment 
option for atherosclerosis-related diseases such as intermit-
tent claudication. It also seems to have a potential for applica-
tion in certain chronic inflammatory diseases such as recur-
rent respiratory tract infections, viral hepatitis, and multiple 
sclerosis. However, further randomized controlled trials (RCT) 
are needed to confirm these findings.
Schlüsselwörter
Padma 28 · Phytotherapie · Tibetische Medizin ·  
Klinische Studien
Zusammenfassung
Hintergrund: Padma 28 ist eine Pflanzenformel aus der Tibeti-
schen Medizin. Sie ist in der Schweiz seit 35 Jahren als Arznei-
mittel bei Symptomen von Durchblutungsstörungen regis-
triert. Über diesen Zeitraum hat sich eine große Menge an 
wissenschaftlicher Literatur angesammelt. Ziel dieses Artikels 
war es, einen Überblick über die klinischen Studien zu geben. 
Methoden: Eine systematische Literatursuche wurde in Pub-
Med, EMBASE und im Cochrane Central Register of Controlled 
Trials (CCRCT) durchgeführt. Die gefundenen klinischen Stu-
dien wurden bezüglich Anwendungsbereich, Wirksamkeit und 
Sicherheit beurteilt sowie auch bezüglich methodischer Quali-
tät und Evidenzlevel. Ergebnisse: 29 klinische Arbeiten (1 
Meta-Analyse, 21 kontrollierte und 7 offene Studien) sowie 3 
retrospektive Fallstudien wurden gefunden. Diese beinhalten 
verschiedene Indikationen und umfassen insgesamt 1704 
Verum- (davon 697 Kinder), 333 Placebo- und 394 unbehan-
delte oder gesunde Kontrollpatienten. Dropouts und Studie-
nabbrüche waren 2,5- bzw. 3,5-mal häufiger in der Placebo- 
als in der Verumgruppe. Der höchste Evidenzlevel für die An-
wendung von Padma 28 zeigte sich bei der Indikation Claudi-
catio intermittens (11 Studien). Hinweise auf Wirksamkeit 
wurden auch bei anderen vaskulären (6 Studien) und verschie-
denen entzündlichen Krankheiten (12 Studien) gefunden. 
Schlussfolgerungen: Die Resultate weisen auf ein günstiges 
Sicherheitsprofil von Padma 28, auch bei den untersuchten 
Kindern (41% der Studienpopulation), und vielfältige An-
wendungsmöglichkeiten hin. Aufgrund der klinischen Evidenz 
erweist sich Padma 28 als sichere und wirksame symptom-
atische Behandlungsoption bei atherosklerosebedingten 
Krankheiten wie z.B. Claudicatio intermittens. Ein gewisses 
Anwendungspotenzial scheint bei bestimmten chronisch-ent-
zündlichen Erkrankungen wie z.B. rezidivierende Atemwegsin-
fekte, Virushepatitis oder Multiple Sklerose zu bestehen. Aller-
dings müssen diese Ergebnisse in randomisierten kontrollier-
ten Studien (RCT) bestätigt werden.
Note: In Switzerland, Padma 28 (Swissmedic No. 58436) is also available 
under the names Padmed Circosan (Swissmedic No. 60131) and Arteria-vita 
(Swissmedic No. 62863).
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Results
From a time span of almost 30 years, 30 publications were 
found: 1 meta-analysis, 26 publications reporting on 28 clinical 
trials, and 3 retrospective case studies (RC). They include a 
total of 1,704 verum patients (per protocol) as well as 333 pla-
cebo and 394 untreated or healthy controls (fig. 1). The inten-
tion-to-treat (ITT) numbers were 1726 in the verum and 355 in 
the placebo group. The rate of dropouts and withdrawals were 
2.3% in the verum and 5.8% in the placebo group; the rates of 
adverse events (AE) were 2.2% and 7.8%, respectively. The 
studies were conducted in patients with intermittent claudica-
tion, other vascular diseases, lipid metabolism disturbances, 
and with inflammatory/immunological conditions.
Padma 28 in Intermittent Claudication
On intermittent claudication, 11 studies were found (table 
1). They included 266 verum and 204 placebo patients (ITT 
266 and 225). 1 meta-analysis, 8 randomized controlled trials 
(RCT) and 1 controlled trial (CT) were in peripheral artery 
disease (PAD) Fontaine stage II [5–14] (table 1). Of the stud-
ies found, the trials in this group were of the highest methodi-
cal quality and, due to a meta-analysis [5], also had the highest 
level of evidence according to the NHMRC [4]. For the meta-
analysis, the raw data of 5 CTs [6–10] were re-analyzed ac-
cordingly to ITT for pooling, and a significant increase of the 
maximum walking distance (MWD) was found. An increase 
of >100 m was rated as clinically significant and was found in 
18.2% of the verum and 2.1% of the placebo patients (p < 0.001; 
number needed to treat: 6.2). The meta-analysis additionally 
showed small but statistically significant effects in  decreasing 
blood glucose, blood lipids, and systolic as well as  diastolic 
blood pressure [5]. 3 trials in intermittent claudication were 
not included in the meta-analysis, 2 because of other clinical 
endpoints and 1 because of another indication (PAD Fon-
taine stages III and IV). 1 RCT analyzed the ankle/brachial 
index (ABI) and the exercise-induced blood pressure drop in 
patients with intermittent claudication [11]. While the ABI 
did not significantly change, the pressure drop after treadmill 
Introduction
Padma 28 is a complex herbal preparation containing 20 
herbal substances, calcium sulfate, and natural camphor. It is 
based on the Tibetan Medicine and has been registered as a 
drug in Switzerland since 1977 (Swissmedic No. 58436) for 
symptoms of circulatory disorders. The formula has been the 
object of scientific research for decades and it is a well-docu-
mented complex multi-compound herbal drug. Padma 28 acts 
according to a multi-target mechanism and has shown anti-in-
flammatory, antioxidant and some antimicrobial effects, as 
well as anti-coagulatory and anti-proliferative properties [1]. 
Such herbal combination drugs are not only the sum of their 
components but they build a genuine, complex active com-
pound in which the single chemical substances are present in 
minute dosages and simultaneously act on different biochemi-
cal pathways to achieve their clinical effect [2]. The network 
character of the herbal preparation leads to a potentially 
broader spectrum of indications than is known for most syn-
thetic monosubstance drugs. The aim of the present review is 
to give an overview of the clinical trials on Padma 28 in any 
investigated indication and to discuss efficacy and safety as-
pects of the preparation.
Material and Methods
Literature Search
Clinical studies on Padma 28 published in German or English were 
systematically searched in the PubMed, EMBASE and Cochrane Central 
Register of Controlled Trials (CCRCT) databases, from their beginning 
up to February 2007. Further data sources were the collected literature of 
Padma Inc. and the list of references of the studies found. If a trial was 
published twice, this study was included only once.
Methodical Quality and Level of Evidence
The studies were assessed regarding methodical quality and level of 
evidence according to Jadad et al. [3] and the National Health and Medi-
cal Research Council (NHMRC) of the Commonwealth of Australia [4], 
respectively.
Fig. 1. Number of patients treated with Padma 
28 or placebo and of controls (untreated or 
healthy) in different indications (only clinical 
trials).
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walking exercise was significantly decreased with Padma 28 
(p = 0.031) and the ischemic window decreased (p = 0.040). 
Another RCT in intermittent claudication patients, analyzing 
blood coagulation parameters and the oxidative burst re-
sponse of monocytes, found significantly improved fibrino-
lytic activity and a decreased oxidative burst response (both 
p <0.05) [13]. The oldest published study was in patients with 
PAD Fontaine stages III and IV and found an improvement 
of cramps and paresthesias and pain-free walking distance as 
well as a reduction of resting pain under verum [14].
Padma 28 in Other Vascular Diseases and Lipid Metabolism
In other atherosclerotic diseases than intermittent claudi-
cation, 4 studies were found. They included 224 verum, 99 pla-
cebo, and 60 untreated control patients (table 1). 1 CT in pa-
tients with impaired intellectual function due to atherosclero-
sis found an improvement in correct reasoning, memory and 
sleep disturbances as well as lowering of increased blood pres-
sure in patients with Padma 28 (n = 85) compared to placebo 
(n = 20) [15]. 1 RCT in patients after ischemic brain stroke 
found an improvement in functional efficiency according to 
Karnofsky scale and immune parameters such as lymphocyte 
populations in patients with the preparation compared to 
standard treatment (n = 60 each) [16]. 2 placebo-controlled, 
cross-over CT in patients with angina pectoris analyzed the 
frequency of attacks, the use of glyceryl trinitrate tablets, and 
the exercise tolerance (n = 79) and found improvements of 
these parameters [17, 18].
A further 2 studies measured changes in blood lipid me-
tabolism. They included 63 verum and 30 placebo patients 
(ITT 64 and 31) as well as 19 healthy controls. 1 RCT showed 
a reduction of the oxidizability of blood lipids by the prepara-
tion [19] and 1 CT found a significant reduction of triglycer-
ides or cholesterol in patients with hypertriglyceridemia or 
hypercholesterolemia, respectively [20]. Additionally, the 
treatment normalized the oscillatory potentials, a marker for 
increased blood lipids and early atherosclerosis.
Padma 28 in Infectious and Immunological Diseases
In various inflammatory conditions of infectious or autoim-
mune origin, 15 studies were found. They included 1,004 
verum patients (ITT 1011), 265 untreated and 50 healthy con-
trols. 6 of these (4 CT and 2 open studies) were conducted in 
recurrent respiratory tract infections in children [21–25], 
which included by far the largest patient groups with 633 
verum patients (ITT 636), 205 untreated, and 40 healthy con-
trols (table 1). They found a decrease in the frequency of in-
fections as well as an improvement of immunologic parame-
ters such as lymphocyte numbers and subsets as well as 
phagocytic activity by the Padma 28 treatment compared to 
controls. 2 open trials in 44 patients with viral hepatitis B 
showed improved serological status and biochemical parame-
ters [26, 27]. 1 RCT in patients with progressive multiple scle-
rosis found an improvement in 44% and a deterioration in 
12% of the verum group compared to zero improvement but 
40% deterioration in patients with symptomatic treatment 
(analgesics, spasmolytics) alone over 1 year of treatment [28]. 
1 comparative study (comparison of treatment with another 
multi-herbal formula) in 23 patients with duodenal peptic 
ulcer showed complete remission in 43.5% of the patients and 
improvement in another 43.5% treated with the phytothera-
peutic, as assessed by endoscopy [29]. In 1 open pilot study, a 
stabilization of lymphocyte subsets (total T cells, helper-in-
ducer cells, suppressor T cells, Leu 2+, 7+ T cells, NK cells) 
and an increase in phagocytic activity was found in 15 human 
immunodeficiency virus (HIV)-positive verum-treated pa-
tients [30]. 1 trial including 12 patients with juvenile chronic 
arthritis showed a decrease of pain and swelling and of the 
number of affected joints in 83.3% of the treated patients, as 
well as an improvement of immune parameters (decrease of 
the erythrocyte sedimentation rate, increase of the CD4/CD8 
ratio) [31].
Retrospective Case Studies
Besides the clinical trials, the literature search produced 3 
RC. 1 of them collected data on the indications in which 
Padma 28 was used by Swiss physicians, as well as on the effi-
cacy and tolerability as assessed by physicians and patients 
[32]. 15 physicians reported on 147 individual patients with 
226 symptoms, of which 75% were due to cardiovascular dis-
orders like peripheral arterial disease (PAD), angina pectoris, 
and cerebral circulatory disorders. The efficacy was rated as 
‘good’ in 76% and 78% of the cases by the physicians and the 
patients, respectively. In 1 RCS in 49 patients (ITT 53) with 
dental pulpitis without a clear indication for an immediate 
root canal treatment, 73% of the patients were free of pain 
within 2 months of the treatment and a root canal was still 
necessary in 18% [33]. 1 RCS was performed in the indication 
of chronic active hepatitis B, for which there are also data 
from 2 open trials. In 90% of the 126 adults and 52 children 
treated with the preparation over a period of 2 years, a dis-
tinct improvement in serological parameters and/or in blood 
parameters was found [34].
Dosage and Treatment Duration
The dosage and duration of the treatment with Padma 28 
varied considerably, e.g., in RC, the duration ranges from 
days to years. In the cardiovascular indications, the treatment 
duration was generally 16 weeks; in immunological indica-
tions, it was mostly 4–6 weeks. In the majority of the adult 
patients, the dosage was 2–3 × 2 tablets/capsules daily, in chil-
dren it was 3 × 1, and in children of <3 years it was 3 × ½ tab-
let daily.
Safety and Tolerability
In 8 of the 29 studies there was no reporting on dropouts 
and AE. AE were relatively few (n = 39), and serious AE 
were rare (n = 9) and largely related to the underlying disease. 
Dropouts and withdrawals were about 2.5 times more fre-
quent in the placebo than in the verum group. In the placebo 
group, the reasons for withdrawals were mainly worsening of 
the condition, failure to improve, and AE, while in the verum 
group they were poor compliance, insufficient efficacy, and 
AE. AE were about 3.5 times more frequent in the placebo 
than in the verum group. The most common AE in both 
groups were mild gastrointestinal symptoms, and in some 
cases, tiredness and skin conditions were reported. Neverthe-
less, the available results suggest a good safety and tolerability 
of Padma 28.
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This may partly explain why Padma 28 has also shown 
some efficacy in different inflammatory diseases. Many stud-
ies in these indications were done in Poland [39]. They gener-
ally date back before the implementation of International 
Conference on Harmonization (ICH) guidelines and are thus 
of a quite lower quality than today’s standards and, except for 
the study in multiple sclerosis [28], were not placebo-control-
led. In Poland, the preparation has been used since decades 
also in pediatric patients. This is reflected by the fact that 
most clinical data were found in only 1 indication in children. 
Of the 1704 patients treated with Padma 28 in the clinical 
studies and RCSs, 697 (41%) were children, and the indica-
tion in 633 (37% of the patients) was recurrent respiratory 
lower tract infections. However, in other countries, e.g. in 
Switzerland, there are no dosages for children given in the 
package insert because the indication is limited to symptoms 
of impaired circulation, which usually appear only in adults.
Studies in other inflammatory indications such as in dental 
pulpitis, viral hepatitis, or multiple sclerosis indicate a possible 
therapeutic value of the formula in these fields, and the results 
would merit further investigation in RCT. Nevertheless, the 
RCS of Bommeli et al. [32] showed that Padma 28 may be 
used in indications besides its registered use of circulatory dis-
orders by medical practitioners, mainly as a supportive treat-
ment in cardiovascular disorders and chronic inflammatory 
conditions. Because of its favorable safety profile and high tol-
erability, such a use seems justified, especially in chronic con-
ditions where a ‘gold standard treatment’ is missing.
Regarding the possibility of drug interactions, none have 
been reported in the 3 decades of use in Western countries. 
Nevertheless, CT are urgently needed to obtain reliable data.
Conclusions
The formula Padma 28 has been established in Europe for 
35 years, not only in the treatment of patients but also in ex-
perimental and clinical research. The body of evidence shows 
efficacy of the formula in atherosclerosis and supports its use 
in cardiovascular disorders as well as in some inflammatory 
conditions. A meta-analysis, as the highest level of evidence, 
is available for the treatment of PAD. Other studies show also 
some efficacy in chronic inflammatory conditions and suggest 
possible positive effects, e.g. in chronic recurrent infections in 
children, chronic active hepatitis B, and multiple sclerosis. 
The studies included 1,704 verum-treated patients, 41% of 
them children, and show the formula to have a favorable 
safety profile. In summary, Padma 28 offers a safe and effec-
tive symptomatic treatment option in PAD. In view of its 
good tolerability in other forms of atherosclerosis and chronic 
inflammatory diseases, the study findings give a kind of ra-
tionale for its use in other clinical conditions, although further 
studies are urgently needed to confirm these data.
Disclosure Statement
C.V. is an employee of Padma Inc. Otherwise the authors declare no 
conflict of interest.
Quality of the studies and level of evidence
The level of evidence according to the NHMRC (best I, 
lowest IV) was the highest in the indication of PAD Fontaine 
stage II. Most of the studies had a level II except 1 meta-anal-
ysis of level I [5], 1 cross over study of III-1 [8] and 1 open 
study of level IV [14]. The Jadad score (best 5, lowest 0) for 
methodical quality assessment is applicable only in rand-
omized studies. Of the 8 studies in IC 1 had a Jadad score of 5, 
2 scored 3, another 2 scores 1 and 3 scored 0. 
In other cardiovascular diseases and studies on lipid me-
tabolism levels of evidence were mostly III-1 and -2 except 2 
studies of level II with Jadad scores of 0 and 3 [16, 19] and 1 
RCS of level IV [32]. 1 randomized trial in MS had an evi-
dence level of II [28]; the other studies in inflammatory and 
autoimmune diseases were not randomized and had evidence 
levels of III-2 to IV. Low Jadad scores were mainly found in 
older studies and due to lacking data on the method of rand-
omization, blinding, and dropouts and withdrawals. The qual-
ity of the studies reflects the state of research at the time they 
were conducted.
Discussion
The systematic review produced a relatively high number 
of clinical studies on Padma 28, with 1,330 verum patients 
(1,704 if RC are included) and 727 controls. The studies origi-
nate from a time span of over 30 years and encompass a broad 
field of indications. From a Western medical point of view, 
this is a very broad spectrum of applications. However, from 
the traditional context of Tibetan Medicine this reflects the 
actual use in practice. Here, the formula Gabur 25, on which 
Padma 28 is based, is used as a general anti-inflammatory 
treatment and in so-called ‘hidden fever’, which could be 
translated as chronic inflammatory disorders [35]. Moreover, 
this formula is specifically used in disturbed blood circulation, 
to support wound healing, and in inflammations of various 
origins, especially in respiratory tract infections.
In the Western context, the formula is mainly used in circu-
latory disorders. The focus of the clinical trials lies in athero-
sclerotic diseases such as PAD, which is a manifestation of 
generalized atherosclerotic disease [36]. The results of the 
studies in angina pectoris, ischemic stroke, and intellectual 
impairment due to atherosclerosis support the hypothesis that 
Padma 28 is not only effective in symptoms of atherosclerosis 
of the leg and pelvic arteries leading to intermittent claudica-
tion. With its broad spectrum of systemic anti-inflammatory 
effects, it might also be effective in other atherosclerotic dis-
eases. The herbal formula seems to act according to a multi-
target mode of action, on the basis of which different patho-
genic pathways are modulated at the same time [1, 2, 37]. 
Among other mechanisms, anti-hyperlipidemic and antioxida-
tive activities seem to play a role [1, 19, 20, 38]. Further fac-
tors contributing to its anti-atherosclerotic effects are various 
anti-inflammatory and immunomodulatory activities [1, 13, 
16, 21–23]. Inflammation is not only a contributor to athero-
genesis but also seems to be a common denominator between 
different chronic inflammatory diseases, and obviously plays a 
role in autoimmune diseases.
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